Leishmaniasis treatment using Triazole-phtalimides as chemotherapeutic agents
Problem
The different clinical forms of leishmaniasis (cutaneous, mucocutaneous, and visceral) share a common treatment approach involving toxic chemotherapy and serious side effects, leading to the development of treatment resistance. Thus, the search for more specific drugs against parasites, without causing harm to the host, is still needed.
Solution
The technology relies on the use of molecules containing the compounds triazole and phthalimide, obtained through a cheap and high-yield method, as leishmanicidal agents for the treatment of leishmaniasis. The combination of molecules with different modes of action into a single chemical entity can reduce the side effects and the emergence of resistance, observed in conventional medications against leishmaniasis.
Differential
|
trending_down
Reduced toxicity |
face
Less chance of developing resistance |
monetization_on
Cheap and efficient synthesis |
Development stage
What we are searching for
Partners to advance through the stages of pre-clinical and clinical studies of the technology and in obtaining the molecule on a large scale.
Inventors
| Regina Celia Bressan Queiroz de Figueiredo |
 |
| Welson Vicente da Silva |
|
| Vera Lucia de Menezes Lima |
|
| Ronaldo Nascimento de Oliveira |
|
| Vanderlan Nogueira Holanda |
|
Intellectual Property
|
|
 |
|||||||||||||||
|
Use your phone camera to scan the QR Code:
|
|
|||||||||||||||
O conteúdo deste portal pode ser utilizado para todos os fins não comerciais, respeitados e reservados os direitos morais dos autores.
